POULTRY ANTIBIOTIC MARKET ANALYSIS

Poultry Antibiotic MarketSize and Trends

The global poultry antibiotic market size is estimated to be US$ 2.0 Billion in 2023. The market is expected to experience a moderate growth rate in the coming years, with a projected CAGR of 6% from 2023 to 2030. This would result in an estimated market size of US$ 3.0 Billion by the end of 2030.

Poultry Antibiotic Market Trends:

• Focus on animal welfare: Consumers are becoming more concerned about the welfare of animals, including those in the poultry industry. This is leading to a greater focus on disease prevention and treatment, as well as the adoption of more humane production practices. For instance, in November 2022, the governments of Canada and Ontario contributed up to US$ 1.5 million through the Canadian Agricultural Partnership to assist qualifying non-supply-managed poultry operations and allied agri-businesses in increasing biosecurity efforts to minimize the spread of highly pathogenic avian influenza.
• Shift towards natural and organic products: There is a growing trend towards natural and organic products in the food industry, including the poultry industry. This is driving demand for antibiotic-free and organic poultry products and presenting opportunities for companies to differentiate themselves in the market.
• Increased regulation of antibiotic use: Governments and regulatory bodies around the world are increasingly regulating the use of antibiotics in the poultry industry, in order to combat antibiotic resistance and protect human health. This is leading to the adoption of alternative disease prevention and treatment strategies. For instance, in January 2023, a coalition of public health advocacy groups filed a lawsuit against the US Food and Drug Administration (FDA) and its Center for Veterinary Medicine (CVM) to protect the safety of consumers, meat processing workers, and farming communities, challenging the FDA's and CVM's refusal to phase out unnecessary antibiotic use in animal agriculture. Antibiotic-resistant bacteria are becoming more common in the U.S. and are the cause of about 2.8 million illness cases and 35,000 fatalities annually due to misuse of these drugs.